Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 28, 2018

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a drug called ocrelizumab on a specific type of brain cells involved in the immune response for patients with Multiple Sclerosis (MS). Ocrelizumab has already shown promising results in reducing the frequency of relapses and slowing down disability progression in both the relapsing and primary progressive forms of MS. The researchers want to understand whether ocrelizumab can also positively impact the activation of certain immune cells in the brain that are difficult to assess with standard imaging techniques like MRI.

To participate in this trial, individuals aged 18 to 60 with a confirmed diagnosis of relapsing or primary progressive MS may be eligible. Key requirements include having had an active form of the disease and not having undergone certain treatments recently. Participants will undergo imaging tests to monitor their condition and the effects of the treatment. This trial is currently recruiting participants, and anyone interested should discuss it with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion criteria for all MS subgroups:
• • 1. Signed informed consent form
• • 2. Able to comply with the study protocol, in the investigator's judgment
• • 3. Social security registration
• • 4. Age 18 - 60 years, inclusive
• • 5. For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of study drug.
• • RMS
• • 1. Have a definite diagnosis of RMS, confirmed as per the revised McDonald 2010 criteria (Polman et al. 2011);
• • 2. Absence of history of Secondary Progressive Multiple Sclerosis (SPMS) or history of Primary Progressive Multiple Sclerosis (PPMS)
• • 3. Have an active disease: Activity determined by clinical relapses and/or MRI activity (contrast-enhancing lesions; new or unequivocally enlarging T2 lesions assessed at least annually (Lublin et al. 2014))
• • 4. Neurological stability for ≥30 days prior to both screening and baseline
• • 5. EDSS of 0.0 to 5.5, inclusive, at screening
• • 6. Have a length of disease duration, from first symptom, of \< 15 years
• • 7. Have received no more than first line injectable treatments (i.e. IFNs and GA, possible switchs within this class) + 1 other treatment (e.g. teriflunomide, DMF, fingolimod, natalizumab, no switch allowed within this group). More details in section 6.1.1.2.1
• 8. Have a suboptimal response to the last received DMT: a suboptimal response is defined by having at least one of the following events while being on a stable dose of the same DMT for at least 6 months:
• • 1. One or more clinically reported relapse(s)
• • 2. OR one or more T1 Gd-enhanced lesion(s)
• • 3. OR one or more new and/or enlarging T2 lesions on MRI
• • 9. In addition, in patients receiving stable doses of the same approved DMT for more than a year, at least one of the above events must have occurred within the last 12 months of treatment with this DMT.
• • RMS
• • 1. Diagnosis of SPMS according to Lublin et al. 2014 criteria
• • 2. Prior history of RRMS (Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
• • 3. Have an active disease during the two years preceding the study entry: Activity determined by clinical relapses and/or MRI activity (contrast-enhancing lesions; new or unequivocally enlarging T2 lesions assessed at least annually (Lublin et al. 2014))
• • 4. Evidence of any disability progression unrelated to relapse within the 2 year period prior to study baseline. Progression in the last year will be reported by the treating physician and documented using a disease progression rating system checklist (see Appendix 1)
• • 5. Progression is defined as steadily increasing objectively documented neurologic dysfunction/disability without unequivocal recovery (fluctuations and phases of stability may occur) (Lublin, 2014)
• • 6. Absence of history of Primary Progressive Multiple Sclerosis or Progressive Relapsing Multiple Sclerosis at screening
• • 7. EDSS at screening ≤ 6.5points
• • 8. Score of ≥ 2.0 on the Functional Systems (FS) scale for the pyramidal system that is due to lower extremity findings
• • 9. Disease duration from the onset of Secondary Progressive MS symptoms of less than 10 years if baseline EDSS ≤5
• • 10. Disease duration from the onset of Secondary Progressive MS symptoms of less than 15 years if baseline EDSS \>5
• • 11. Have received no more than first line treatments (either injectable, i.e. IFNs and GA, or oral, either teriflunomide and dimethyl fumarate, possible switchs within this group) + 1 second line treatment (e.g., fingolimod, natalizumab, no switch allowed within this group).
• • PPMS
• 1. Diagnosis of PPMS in accordance with the 2010 revised McDonald criteria :
• • 2. One year of disease progression (retrospectively or prospectively determined)
• 3. Plus 2 of the 3 following criteria :
• • 1. Evidence for DIS in the brain based on ≥ 1 T2 lesions in at least 1 area characteristic for MS (periventricular, juxtacortical, or infratentorial)
• • 2. Evidence for DIS in the spinal cord based on ≥ 2 T2 lesions in the cord
• • 3. Positive CSF (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index)
• • 4. Absence of history of Relapsing Remitting Multiple Sclerosis, Secondary Progressive, or Progressive Relapsing Multiple Sclerosis at screening
• • 5. Evidence of any disability progression unrelated to relapse within the 2 year period prior to study baseline. Progression in the last 2 year will be reported by the treating physician and documented using a disease progression rating system checklist (see Appendix 1)
• • 6. EDSS at screening between 2.0 and 6.5 points
• • 7. Score of ≥ 2.0 on the Functional Systems (FS) scale for the pyramidal system that is due to lower extremity findings
• • 8. Disease duration from the onset of MS symptoms of less than 10 years if baseline EDSS ≤5
• • 9. Disease duration from the onset of MS symptoms of less than 15 years if baseline EDSS \>5
• Healthy volunteers (20 subjects):
• • 1. Signed informed consent form
• • 2. Able to comply with the study protocol, in the investigator's judgment
• • 3. Social security registration
• • 4. Age 18 - 60 years, inclusive
• • 5. For women of childbearing potential: agreement to use an acceptable birth control method during the research period and for at least 1 cycle after the PET-MRI.
• • 1. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
• • 2. The following are acceptable contraceptive methods: progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, and cap, diaphragm, or sponge with spermicide. A combination of male condom with cap, diaphragm, or sponge with spermicide (double barrier methods) is considered acceptable
• • 3. Pregnancy tests will be performed at each study visit for women of childbearing potential.
• Exclusion Criteria:
• • 1. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight ≥ 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, contraindication to gadoteric acid etc.).
• • 2. Impossibility to complete a PET scan: pregnancy, nuclear medicine irradiation in the year preceding baseline visit for clinical research and one year after the end of their participation in the study, lactation.
• 3. Known presence of other neurological disorders, including but not limited to, the following:
• • 1. History of ischemic cerebrovascular disorders (e.g., stroke, transient ischemic attack) or ischemia of the spinal cord
• • 2. History or known presence of CNS or spinal cord tumor (e.g., meningioma, glioma)
• • 3. History or known presence of potential metabolic causes of myelopathy (e.g., untreated vitamin B12 deficiency)
• • 4. History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy)
• • 5. History of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis; MELAS \[mitochondrial myopathy, encephalopathy, lactic acidosis, stroke\] syndrome)
• • 6. Neuromyelitis optica
• • 7. History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Behçet's disease)
• • 8. History or known presence of sarcoidosis
• 9. History of severe, clinically significant brain or spinal cord trauma (e.g., cerebral contusion, spinal cord compression) - General Health:
• • 1. Pregnancy or lactation 2. Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressant drugs during the course of the study 3. History or currently active primary or secondary immunodeficiency 4. Lack of peripheral venous access 5. Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal or any other significant disease that may preclude patient from participating in the study 6. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies 7. Congestive heart failure (New York Heart Association \[NYHA\] III or IV functional severity) 8. Known active bacterial, viral, fungal, mycobacterial infection or other infection \[including tuberculosis \[TB\] or atypical mycobacterial disease (but excluding fungal infection of nail beds)\] or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit; Note: Active infections should be treated and effectively controlled before possible inclusion in the study 9. History or known presence of recurrent or chronic infection 10. History of malignancy, including solid tumors and hematological malignancies, except basal cell carcinoma, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that have been previously completely excised with documented, clear margins 11. History of alcohol or drug abuse within 24 weeks prior to baseline 12. History or laboratory evidence of coagulation disorders 13. History of major opportunistic infections (i.e. cryptococcosis, Pneumocystis pneumonia, progressive multifocal leukoencephalopathy \[PML\]) 14. History of recurrent aspiration pneumonia requiring antibiotic therapy 15. Hypersensitivity to the active substance or to any of the excipients (Sodium Acetate Trihydrate, Glacial Acetic Acid, Trehalose Dihydrate, Polysorbate 20, Water for Injection)
• * Laboratory Findings:
• • 1. TSPO polymorphism indicating a low affinity profile.
• • 2. Positive serum β human chorionic gonadotropin (hCG) measured at screening and before each PET-Scan procedure
• • 3. Positive screening tests for hepatitis B (hepatitis B surface antigen \[HBsAg\] positive, or positive hepatitis B core antibody \[total HBcAb\] confirmed by a positive viral DNA polymerase chain reaction \[PCR\]) or hepatitis C (HepCAb)
• • 4. Lymphocyte count below lower limit of normal (LLN)
• • 5. CD4 count \<300/μL.
• • 6. Absolute neutrophil count \<1.0 × 103/µL
• * Medications:
• • 1. Receipt of a live vaccine or attenuated live vaccine within 6 weeks prior to the baseline visit. In rare cases when patient requires vaccination with a live vaccine, the screening period may be extended but cannot exceed 8 weeks
• • 2. Treatment with any investigational agent within 24 weeks of screening or five half-lives of the investigational drug (whichever is longer) or treatment with any experimental procedures for MS (e.g., treatment for chronic cerebrospinal venous insufficiency)
• • 3. Treatment with Flumitrazepam, triazolam, diazepam
• * Treatment of Multiple Sclerosis:
• • 1. Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
• • 2. Systemic corticosteroid therapy within 4 weeks prior to screeningii
• • 3. Treatment with IV immunoglobulin (Ig) within 12 weeks prior to baseline
• • 4. Any previous treatment with alemtuzumab, daclizumab, anti-CD4, total body irradiation or bone marrow transplantation
• • 5. Any previous treatment with biotin in the last month prior to screening
• • 6. Previous treatment with mitoxantrone, cyclosporine or cladribine in the last 96 weeks
• • 7. Previous treatment with azathioprine, cyclophosphamide, mycophenolate mofetil,methotrexate, or laquinimod in the last 24 weeks
• 8. Previous treatment with teriflunomide, unless an accelerated elimination procedure is implemented before screening visit. Accelerated elimination procedure after stopping treatment with teriflunomide:
• • 1. cholestyramine 8g is administered 3 times daily for a period of 11 days, or cholestyramine 4g three times a day can be used, if cholestyramine 8g three times a day is not well tolerated,
• • 2. alternatively, 50g of activated powdered charcoal is administered every 12 hours for a period of 11 days
• • 9. Previous treatment with natalizumab in the last 12 weeks
• • 10. Previous treatment with fingolimod or dimethyl fumarate if at baseline the lymphocyte count is below lower limit of normality (LLN). Apart from the lymphocytes count within normal ranges, 12 weeks of a washout period of fingolimod or dimethylfumarate would be required before the start of ocrelizumab administration
• • 11. History of recurrent aspiration pneumonia requiring antibiotic therapy
• • 12. Treatment with fampridine/dalfamipridine (Fampyra®)/Ampyra®) unless on stable dose for ≥ 30 days prior to screening. Wherever possible, patients should remain on stable doses throughout the 96-week treatment period
• • 13. Treatment with β interferons, glatiramer acetate, plasmapheresis, or other immunomodulatory therapies within 4 weeks prior to baselinei
• Healthy volunteers:
• • 1. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight ≥ 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, contraindication to acid gadoteric etc.)
• • 2. Impossibility to complete a PET scan: pregnancy, nuclear medicine irradiation in the year preceding baseline visit for clinical research
• • 3. Known presence of any neurological disorders
• • 4. Pregnancy or lactation
• • 5. Lack of peripheral venous access
• • 6. Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal infectious, neoplasic or any other significant disease that may preclude patient from participating in the study
• • 7. History of alcohol or drug abuse within 24 weeks prior to baseline
• • 8. TSPO polymorphism indicating a low affinity profile.
• • 9. Treatment with Flumitrazepam, triazolam, diazepam